ACTRN12620000104954已完成1 期
A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MET642 after single and multiple ascending oral dose administration in healthy subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Metacrine
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 50 Years（—）
- 性别
- All
入选标准
- •Healthy subjects without any co-morbidities or clinically significant disease.
排除标准
- •Smokers and subjects with a history of drug and/or alcohol abuse or current drug and alcohol abuse, and subjects with a history of clinically significant disease.
研究者
相似试验
未知
3 期
A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients with active rheumatoid arthritis who have an inadequate response to anti-TNF-alpha agentsRheumatoid ArthritisJPRN-jRCT2080221561ovartis Pharma K.K.
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-PTYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasiaImprovement of nocturnal voiding frequency, in subjects with LUTS associated with BPHMedDRA version: 6.1Level: PTClassification code 10004446EUCTR2005-001627-11-ITYAMANOUCHI PHARMA882
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia - RESTORETS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)EUCTR2005-001627-11-FIYamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)1,051
进行中（未招募）
1 期
Evaluation of Efficacy and Safety of Sarilumab in Patients with GCAMedDRA version: 20.0Level: LLTClassification code 10018250Term: Giant cell arteritisSystem Organ Class: 100000004866Giant Cell ArteritisEUCTR2017-002988-18-BESanofi-Aventis Recherche & Développement508